Myasthenia gravis trials in Italy

In Italy 32 Also abroad 123

32 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients with Myasthenia Gravis
Where
Bergamo, Bologna, Genoa, Milan, Naples, Pisa, Rome
Age
18 years and over
People
59 worldwide
Run by
NMD Pharma A/S
See details and how to join2023-507539-40-00 · EU 2023-507539-40-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Where
Bergamo, Florence, Messina, Milan, Naples, Pavia, Pisa, Rome
Age
18 years and over
People
120 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT07463521 · EU 2025-524756-54-00
Phase 3Taking people
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Where
Bergamo, Florence, Messina, Milan, Naples, Pavia, Pisa, Rome
Age
18 years and over
People
100 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT07465289 · EU 2025-524757-14-00
Phase 3Taking people
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Where
Brescia, Milan, Naples, Pavia, Rome
Age
18 years and over
People
199 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT04951622 · EU 2023-504152-97-00
Phase 2/3Taking people
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
Where
Milan
Age
12 years to 17 years
People
8 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT06055959 · EU 2022-502072-23-00
No phaseTaking people
Holistic Assessment and Remote Digital MONitoring of mYasthenia Gravis Via MyoSense 360
Where
Milan, Pavia, Pisa, Roma
Age
18 years and over
People
100 worldwide
Run by
Ad scientiam
See details and how to joinNCT07323316
Phase 2Taking people
ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
Where
Bergamo, Milan, Naples, Rome
Age
18 years and over
People
40 worldwide
Run by
argenx
See details and how to joinNCT07673627 · EU 2025-522939-33-00
Phase 2/3Enrolling by invitation
Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
Where
Florence, Genoa
Age
2 years to 18 years
People
12 worldwide
Run by
argenx
See details and how to joinNCT05374590 · EU 2023-507379-23-00
Phase 3Taking people
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
Where
Milan, Naples, Pisa, Rome
Age
18 years to 74 years
People
115 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07217587 · EU 2025-521130-28-00
Phase 3Taking people
A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
Where
Pisa, Rome
Age
18 years to 80 years
People
195 worldwide
Run by
Dianthus Therapeutics
See details and how to joinNCT07647510 · EU 2026-525298-38-00
No phaseTaking people
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
Where
Bergamo, Milan, Naples
Age
18 years and over
People
70 worldwide
Run by
argenx
See details and how to joinNCT07294170
Phase 2Taking people
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
Where
Florence, Rome
Age
2 years to 17 years
People
15 worldwide
Run by
Amgen
See details and how to joinNCT06987539 · EU 2025-520993-20-00
Phase 3Taking people
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Where
Bergamo, Bologna, Genoa, Milan, Pavia, Rome, Treviso
Age
18 years and over
People
264 worldwide
Run by
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
See details and how to joinNCT06463587 · EU 2023-507746-83-00
Phase 3Enrolling by invitation
An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
Where
Milan
Age
12 years to 17 years
People
8 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT06435312 · EU 2022-502073-42-00
Phase 1Not yet taking people in Italy
Basket trial for B-cEll driven severe auToimmunE and aLoimmune diseases (chronic Graft vErsUs host diseaSe) treated with anti-CD19 CAR T-cell thErapy
Where
Bologna, Rome
People
24
Run by
Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico
See details and how to join2025-522821-37-00 · EU 2025-522821-37-00
Phase 2/3Taking people
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
Where
Genoa
Age
2 years to 17 years
People
12 worldwide
Run by
argenx
See details and how to joinNCT06392386 · EU 2023-506159-12-00
Phase 2Taking people
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
Where
Bergamo, Milan, Naples, Rome
Age
18 years and over
People
70 worldwide
Run by
argenx
See details and how to joinNCT07284420 · EU 2025-522492-28-00
Phase 2Taking people
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
Where
Bergamo, Bologna, Genova, Milan, Naples, Pisa, Roma
Age
18 years and over
People
84 worldwide
Run by
NMD Pharma A/S
See details and how to joinNCT06414954
Phase 3Taking people
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Where
Bergamo, Bologna, Milan, Naples, Pisa, Rome, Sassari
Age
18 years to 80 years
People
231 worldwide
Run by
Immunovant Sciences GmbH
See details and how to joinNCT07039916 · EU 2024-515979-35-00
No phaseTaking people
PANORAMA: Neuromuscular Organoids for Refractory AChR+ Myasthenia Gravis
Where
Milan
Age
18 years and over
People
40
Run by
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
See details and how to joinNCT07717281
No phaseTaking people
A Study to Evaluate the Impact of Efgartigimod on Overall Disease Experience of People Suffering From Generalized Myasthenia Gravis (gMG) in Italy
Where
Acquaviva delle Fonti, Ancona, Bari, Bergamo, Bologna, Catanzaro, Florence, Genova, Messina, Milan, Monserrato, Naples, Orbassano, Padova, Pavia, Perugia, Pisa, Rimini, Roma, Salerno, San Giovanni Rotondo, Sassari, Treviso, Verona
Age
18 years and over
People
100
Run by
argenx
See details and how to joinNCT07595653
No phaseNot yet taking people in Italy
Thymic Disease, Autoimmunity, and Neuromuscular Junction Integrity in Myasthenia Gravis
Where
Milan
Age
18 years and over
People
40
Run by
IRCCS San Raffaele
See details and how to joinNCT07571525
No phaseTaking people
Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
Where
Rome
People
75 worldwide
Run by
Alexion Pharmaceuticals, Inc.
See details and how to joinNCT06312644
Phase 4Taking people
A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab
Where
Naples, Rome
Age
18 years and over
People
75 worldwide
Run by
Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07221838 · EU 2025-522555-26-00
No phaseTaking people
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
Where
Milan, Naples
Age
18 years and over
People
500 worldwide
Run by
Alexion Pharmaceuticals, Inc.
See details and how to joinNCT04202341